Fangsheng Pharmaceutical: Bisoprolol Amlodipine Tablets obtained the "Drug Registration Certificate"

Fangsheng Pharmaceutical announced that on March 3, its wholly-owned subsidiary Jianmeng Pharmaceuticals received the Drug Registration Certificate for Bisoprolol Amlodipine Tablets issued by the National Medical Products Administration, allowing for production. The total investment in this drug project is approximately 8.98 million yuan. In the first three quarters of 2025, the sales of this drug exceeded 100 million yuan, a year-on-year increase of 248.78%. The acquisition of this certificate enriches the company's cardiovascular and cerebrovascular drug product line, enhancing its market competitiveness. However, drug sales are influenced by various factors, and the short-term impact on performance is not significant.